Related Experiment Video
Updated: Feb 24, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
mTOR co-targeting strategies for head and neck cancer therapy
Zhiyong Wang1,2, Juan Callejas Valera1, Xuefeng Zhao1,2
1Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. There is an urgent need to develop effective therapeutic approaches to prevent and treat HNSCC. Recent deep sequencing of the HNSCC genomic landscape revealed a multiplicity and diversity of genetic alterations in this malignancy. Although a large variety of specific molecules were found altered in each individual tumor, they all participate in only a handful of driver signaling pathways. Among them, the PI3K/mTOR pathway is the most frequently activated, which plays a central role in cancer initiation and progression. In turn, targeting of mTOR may represent a precision therapeutic approach for HNSCC. Indeed, mTOR inhibition exerts potent anti-tumor activity in HNSCC experimental systems, and mTOR targeting clinical trials show encouraging results. However, advanced HNSCC patients may exhibit unpredictable drug resistance, and the analysis of its molecular basis suggests that co-targeting strategies may provide a more effective option. In addition, although counterintuitive, emerging evidence suggests that mTOR inhibition may enhance the anti-tumor immune response. These new findings raise the possibility that the combination of mTOR inhibitors and immune oncology agents may provide novel precision therapeutic options for HNSCC.
Insights
Targeting the PI3K/mTOR pathway shows promise for head and neck squamous cell carcinoma (HNSCC) treatment. Combining mTOR inhibitors with immunotherapy may overcome drug resistance and improve outcomes for advanced HNSCC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a prevalent global malignancy requiring novel therapeutic strategies.
- Genomic studies reveal diverse genetic alterations in HNSCC, converging on key signaling pathways like PI3K/mTOR.
- The PI3K/mTOR pathway is frequently activated, driving cancer initiation and progression in HNSCC.
Purpose of the Study:
- To investigate the therapeutic potential of targeting the PI3K/mTOR pathway in HNSCC.
- To explore strategies for overcoming drug resistance to mTOR inhibitors in advanced HNSCC.
- To evaluate the synergistic effects of combining mTOR inhibitors with immune oncology agents.
Main Methods:
- Analysis of HNSCC genomic landscape using deep sequencing.
- In vitro and in vivo experimental systems to assess mTOR inhibition efficacy.
- Review of clinical trial data for mTOR targeting agents in HNSCC.
- Investigation into the molecular mechanisms of drug resistance and immune response modulation.
Main Results:
- mTOR inhibition demonstrates significant anti-tumor activity in HNSCC models.
- Clinical trials of mTOR inhibitors show encouraging preliminary results.
- Drug resistance is a challenge in advanced HNSCC, suggesting combination therapies.
- mTOR inhibition may enhance anti-tumor immune responses.
Conclusions:
- Targeting the PI3K/mTOR pathway represents a viable precision medicine approach for HNSCC.
- Combination strategies, including co-targeting and immunotherapy, may offer more effective treatment options for advanced HNSCC.
- Further research into mTOR inhibition combined with immune oncology agents holds promise for novel HNSCC therapies.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
09:23Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
Published on: October 10, 2025
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...